MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.680
-0.080
-2.13%
After Hours: 3.680 0 0.00% 16:00 10/22 EDT
OPEN
3.820
PREV CLOSE
3.760
HIGH
3.826
LOW
3.640
VOLUME
40.96K
TURNOVER
--
52 WEEK HIGH
5.40
52 WEEK LOW
1.039
MARKET CAP
101.80M
P/E (TTM)
-1.4687
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that Sandra Aung, Ph.D. joined the Company as Senior Vice President, Chief Clinical Development Officer.
PR Newswire · 10/12 13:30
OncoSec Announces Appointment Of Senior VP, Chief Clinical Development Officer
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical
Benzinga · 10/12 12:34
OncoSec secures new patent in U.S.; shares up 8%
The USPTO has issued a new patent to OncoSec Medical (ONCS) covering its interleukin-12 (IL-12) based immunotherapy platform, including lead product candidate TAVO, and its proprietary EP gene delivery system.U.S.
Seekingalpha · 10/06 12:59
OncoSec Announces Issuance Of New US Patent Expanding Coverage Of TAVO And Its Gene Delivery Platform
PENNINGTON, N.J. and SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral
Benzinga · 10/06 12:38
OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D
PR Newswire · 08/27 13:30
OncoSec Announces Initiation Of Phase 2 Study At The Moffitt Cancer Center To Evaluate Combination Of TAVO Plus OPDIVO As Neoadjuvant Therapy For Melanoma
Study to Assess the Potential of TAVO in Combination with Anti-PD-1 Checkpoint Inhibitors to Improve Overall Outcomes such as Operability, Pathologic Tumor Response and Long-Term Disease Control in Early Melanoma
Benzinga · 08/27 12:36
OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer will present at the LD 500 Virtual Conference on Wednesday
PR Newswire · 08/25 13:30
OncoSec Medical shares are trading lower after the company announced a common stock offering of 4.61 million shares at $3.25 per share.
Benzinga · 08/17 16:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCS. Analyze the recent business situations of OncoSec Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCS stock price target is 7.38 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 1.04M
% Owned: 3.75%
Shares Outstanding: 27.66M
TypeInstitutionsShares
Increased
6
217.13K
New
11
-61.40K
Decreased
1
5.12K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Independent Director
Margaret Dalesandro
President/Chief Executive Officer/Director
Daniel O'Connor
Chief Operating Officer
Kellie Foerter
Chief Accounting Officer/Controller
Robert DelAversano
Director
Joon Kim
Director
Kevin Smith
Director
Yuhang Zhao
Director
Chao Zhou
Independent Director
James DeMesa
Independent Director
Herbert Lyerly
Independent Director
Robert Ward
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ONCS
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.